Document is current
Any future updates will be listed below
-
Authors
Scholes, Natalie S. https://orcid.org/0000-0002-1053-4079
Bertoni, Martino
Comajuncosa-Creus, Arnau https://orcid.org/0000-0002-9633-7665
Kladnik, Katharina
Guo, Xuefei https://orcid.org/0000-0001-7135-0954
Frommelt, Fabian https://orcid.org/0000-0003-3666-8005
Hinterndorfer, Matthias https://orcid.org/0000-0003-2435-4690
Razumkov, Hlib https://orcid.org/0000-0001-6150-8172
Prokofeva, Polina
Schwalm, Martin P. https://orcid.org/0000-0002-1252-1829
Born, Florian
Roehm, Sandra https://orcid.org/0000-0003-3999-712X
Imrichova, Hana https://orcid.org/0000-0003-0385-1823
Santini, Brianda L.
Barone, Eleonora https://orcid.org/0000-0002-4788-7070
Schätz, Caroline
Muñoz i Ordoño, Miquel https://orcid.org/0009-0003-4391-6393
Lechner, Severin
Rukavina, Andrea https://orcid.org/0000-0001-8254-9360
Serrano, Iciar
Abele, Miriam https://orcid.org/0000-0003-0084-2999
Koren, Anna https://orcid.org/0000-0003-2528-4970
Kubicek, Stefan https://orcid.org/0000-0003-0855-8343
Knapp, Stefan https://orcid.org/0000-0001-5995-6494
Gray, Nathanael S. https://orcid.org/0000-0001-5354-7403
Superti-Furga, Giulio https://orcid.org/0000-0002-0570-1768
Kuster, Bernhard https://orcid.org/0000-0002-9094-1677
Shi, Yigong https://orcid.org/0000-0003-2030-168X
Aloy, Patrick https://orcid.org/0000-0002-3557-0236
Winter, Georg E. https://orcid.org/0000-0001-6606-1437
- License Information
-
More Information
Article History
Received: 15 July 2024
Accepted: 15 October 2025
First Online: 26 November 2025
Competing interests
: S. Kubicek, G.S.-F. and G.E.W. are scientific founders and shareholders of Proxygen and Solgate and shareholders in Cellgate Therapeutics. G.E.W. is on the scientific advisory board of Nexo Therapeutics. The G.E.W. and G.S.-F. laboratories received research funding from Pfizer. B.K. is a founder and shareholder of OmicScouts and MSAID. He has no operational role in either company. N.S.G. is a founder, scientific advisory board member and equity holder in Syros, C4, Allorion, Lighthorse, Voronoi, Inception, Matchpoint, CobroVentures, GSK, Shenandoah (board member), Larkspur (board member) and Soltego (board member). The Gray laboratory receives or has received research funding from Novartis, Takeda, Astellas, Taiho, Jansen, Kinogen, Arbella, Deerfield, Springworks, Interline and Sanofi. The other authors declare no competing interests.
